Papers

The "Papers" page is a library of up to date research papers on subjects which you may find useful when creating articles for us, or doing your own studies.

In addition, there is also some helpful instructions on several ways to gain access to any papers you may need.

• If you have any questions about our library you should contact our lead research librarian LilianaUmbra, who is responsible for managing research requests and this pages content.

Finding papers

• Google Scholar indexes articles, shows citations and "cited bys", impact factor etc.
• Pubmed offers more granular search options.

Getting access

Journal articles are frequently paywalled, requiring an obscene ~$40 per article to see anything besides their abstracts. Here's some ways around:

• If you're a student, your university should have journal access for all IPs on its network. If you make friends with a student, you could ask to borrow their login.
• Even if you're not a student, you can often get a library card at a university library. University library computers will have journal access, so if the library is open to the public you can surf there and save articles to a USB stick.
• Sci-Hub is a proxy that circumvents paywalls for journal access. You can tack .sci-hub.mn on the end of the domain name for a URL you want to access. For instance, if you wanted to go to http://nature.com/some/article.html, change it to http://nature.com.sci-hub.cc/some/article.html. Note that sci-hub is frequently under attack and the legality of using it varies by region, ymmv.
• Library Genesis has a repository of scientific papers. Unlike Sci-Hub, it does not let you access papers that don't already exist in the LibGen repository. However, it is a useful backup if Sci-Hub is down, as Sci-Hub stores a copy of every paper it downloads to LibGen.

• Using Sci-Hub Links extension for Chrome and Firefox can be used to automatically translate DOI to sci-hub links
• The Scholar subreddit lets you post requests for articles. Volunteers will find and upload articles for you, bypassing the paywall.
• Arxiv hosts free pre-publication articles, but very few in the biology realm.

• Due to the volatile nature of which domains are working for sci-hub currently, if any links are broken simply replace the domain of the link with a working one. .mn and .tw work as of 12/12/2017.

Transition related healthcare

Bone Density

• Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis (November 2017)Original

• Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multiscenter Prospective Observational Study (May 2017)Original

• Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents (February 2017)Original

Reproductive Health

• Fertility Preservation for Transgender Adolescents (July 2017)Original

Hormone Replacement Therapy

• Gender-Affirming Pharmacological Interventions for Youth With Gender Dysphoria: When Treatment Guidelines Are Not Enough(November 2017)Original

• Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study (October 2017)Original

• Gender Opportunities in Psychosocial Oncology (September 2017)Original

• Cross-Sex Hormones and Metabolic Parameters in Adolescents With Gender Dysphoria (May 2017)Original

• Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents (July 2016)Original

• Mad men, women and steroid cocktails: A review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors (February 2016)

• A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals (January 2016)Original

• Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals (June 2015)

Risk Analysis

• Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis (November 2017)Original

• Preventive Health for Transgender Men and Women (September 2017)Original

• Is Type 1 Diabetes Mellitus More Prevalent Than Expected in Transgender Persons? A Local Observation (September 2017)

• Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review (August 2017)Original

• Gender Dysphoria and Co-Existing Psychosis: Review and Four Case Examples of Successful Gender Affirmative Treatment (April 2017)Original

Masculinization

Hormone Replacement Therapy

• Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture (November 2017)Original

• Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism (November 2017)Original

• The Response of the Menstrual Cycle to Initiation of Hormonal Therapy in Transgender Men (October 2017)

• Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review (September 2017)Original

• Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients (July 2017)Original

• Testosterone therapy for transgender men (April 2017)Original

• Hormonal and Surgical Treatment Options for Transgender Men (Female-to-Male)(March 2017)Original

• Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis (February 2016)

• High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People (October 2015)

• Antimüllerian hormone levels decrease in female-to-male transsexuals using testosterone as cross-sex therapy (May 2015)Original

• Testosterone treatment and MMPI-2 improvement in transgender men: a prospective controlled study (February 2015)Original

• Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder (September 2013)Original

• Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder (October 2012)Original

• Associations between transition-specific stress experience, nocturnal decline in ambulatory blood pressure, and C-reactive protein levels among transgender men (January 2012)

• Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals (March 2010)

• Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals (September 2009)Original

Genital Reassignment Surgery

• Total vaginectomy and urethral lengthening at time of neourethral prelamination in transgender men (November 2017)Original

• Double flap phalloplasty in transgender men: Surgical technique and outcome of pedicled anterolateral thigh flap phalloplasty combined with radial forearm free flap urethral reconstruction (November 2017)Original

• How Big is Too Big? The Girth of Bestselling Insertive Sex Toys to Guide Maximal Neophallus Dimensions (November 2017)Original

• A Longitudinal Study of Motivations Before and Psychosexual Outcomes After Genital Gender-Confirming Surgery in Transmen (November 2017)

• Phalloplasty with Urethral Lengthening: Addition of a Vascularized Bulbospongiosus Flap from Vaginectomy Reduces Postoperative Urethral Complications (October 2017)Original

• MatriDerm Decreases Donor Site Morbidity After Radial Forearm Free Flap Harvest in Transgender Surgery (October 2017)Original

• Outcomes After Phalloplasty: Do Transgender Patients and Multiple Urethral Procedures Carry a Higher Rate of Complication? (October 2017)Original

• Combined hysterectomy and mastectomy surgery for transgender patients in an integrated health care setting (August 2017)Original

• Mystery and realities of phalloplasty: a systematic review (August 2017)

• An Update on Genital Reconstruction Options for the Female-to-Male Transgender Patient: A Review of the Literature (March 2017)Original

• Feasibility of Vaginal Hysterectomy for Female-to-Male Transgender Men (March 2017)

• Robot-assisted laparoscopic colpectomy in female-to-male transgender patients; technique and outcomes of a prospective cohort study (November 2016)

• The 2011 WPATH Standards of Care and Penile Reconstruction in Female-to-Male Transsexual Individuals (May 2012)

• Clinical applications of the pedicled anterolateral thigh flap in penile reconstruction (January 2011Original

Reproductive Health

• Use of Copper Intrauterine Device in Transgender Male Adolescents (February 2018)Original

• Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents (November 2017)

• From erasure to opportunity: a qualitative study of the experiences of transgender men around pregnancy and recommendations for providers (November 2017)

• Hysterectomy for the Transgendered Male: Review of Perioperative Considerations and Surgical Techniques with Description of a Novel 2-Port Laparoscopic Approach (September 2017)Original

• Pelvic pain in transgender men taking testosterone: Assessing the risk of ovarian cancer(July 2017)Original

• Transgender men's experiences of fertility preservation: a qualitative study (February 2017)Original

• Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals (October 2016)Original

• Transgender men and pregnancy (March 2016)Original

Vocal Therapy

• Trans Male Voice in the First Year of Testosterone Therapy (September 2017)Original

• Effects of testosterone on the transgender male voice (January 2017)Original

• Voice deepening under testosterone treatment in female-to-male gender dysphoric individuals (April 2016)Original

• Voice in female-to-male transsexual persons after long-term androgen therapy (June 2014)Original

Top surgery and binding

• Clinicopathological findings in female-to-male gender-affirming breast surgery (December 2017)Original

• Subcutaneous mastectomy in female-to-male transsexuals: Optimizing perioperative and operative management in 8 years clinical experience (September 2017)Original

• Female-to-Male Chest Reconstruction: A Review of Technique and Outcomes (September 2017)Original

• Chest reconstructive surgeries in transmasculine youth: Experience from one pediatric center (July 2017)Original

• A Review of 101 Consecutive Subcutaneous Mastectomies and Male Chest Contouring Using the Concentric Circular and Free Nipple Graft Techniques in Female-to-Male Transgender Patients (June 2017)Original

• Top Surgery in Transgender Men: How Far Can You Push the Envelope?(April 2017)Original

• Body Image in Transmen: Multidimensional Measurement and the Effects of Mastectomy (November 2016)Original

• Health impact of chest binding among transgender adults: a community-engaged, cross-sectional study (October 2015)Original

• Adding value to rare tissue samples donated to biobanks: characterisation of breast tissue and primary cell cultures obtained from a female-to-male transgender patient (April 2014)Original

Feminization

Hormone Replacement Therapy

• Efficacy and Safety of Pubertal Induction Using 17β-Estradiol in Transgirls (July 2017)Original

• Oestrogen and anti-androgen therapy for transgender women(April 2017)Original

• Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens (December 2012)Original

Risk Analysis

• Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol (November 2016)Original

• A case of first-onset psychosis and repeated relapses secondary to discontinuation of non-prescription estrogen replacement therapy in a transgendered female (April 2016)Original

• Bilateral non-arteritic ischemic optic neuropathy in a transsexual woman using excessive estrogen dosage (February 2014)Original

• Development of systemic lupus erythematosus in a male-to-female transsexual: the role of sex hormones revisited.(November 2013)Original

Genital Reassignment Surgery

• Neovaginal Construction with Pelvic Peritoneum: Reviewing an Old Approach for a New Application (November 2017)Original

• Male-to-Female Sex Reassignment Surgery using the Combined Vaginoplasty Technique: Satisfaction of Transgender Patients with Aesthetic, Functional, and Sexual Outcomes (November 2017)Original

• Gender Confirmation Surgery Using the Pedicle Transverse Colon Flap for Vaginal Reconstruction: A Clinical Outcome and Sexual Function Evaluation Study (November 2017)Original

• Age Is Just a Number: WPATH-Affiliated Surgeons' Experiences and Attitudes Toward Vaginoplasty in Transgender Females Under 18 Years of Age in the United States (April 2017)Original

• Patient-Reported Esthetic and Functional Outcomes of Primary Total Laparoscopic Intestinal Vaginoplasty in Transgender Women With Penoscrotal Hypoplasia (September 2016)Original

• Clinical Characteristics and Management of Neovaginal Fistulas After Vaginoplasty in Transgender Women (June 2016)Original

• Testicular Functions and Clinical Characterization of Patients with Gender Dysphoria (GD) Undergoing Sex Reassignment Surgery (SRS)(November 2015)Original

Reproductive Health

• Andrology of male-to-female transsexuals: Influence of cross-sex hormone therapy on testicular function(September 2017)Original

• Effects of Elevated β-Estradiol Levels on the Functional Morphology of the Testis - New Insights(January 2017)Original

Facial Feminization Therapy

• Formations of Femininity: Science and Aesthetics in Facial Feminization Surgery (October 2017)Original

• Thyroid chondroplasty: Smoothing the thyroid cartilage— A retrospective study of thyroid chondroplasty for feminine neck appearance (August 2017)Original

• Facial Feminization: Systematic Review of the Literature (June 2016)Original

Vocal Therapy

• Perceptual-Auditory and Acoustical Analysis of the Voices of Transgender Women (November 2017)Original

• Pitch Elevation in Male-to-female Transgender Persons—the Würzburg Approach (March 2017)Original

• An ICF Perspective on Voice-related Quality of Life of American Transgender Women (January 2017Original

Standards Of Care & Practice Guidelines

• Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (November 2017)Original

• Gender incongruence: a comparative study using ICD-10 and DSM-5 diagnostic criteria (Oct 7 2017)

• WPATH Standards Of Care 7th Edition

• Guidelines And Protocols For Comprehensive Primary Care For Trans Clients (2015)

• Health Care for Transgender Patients: Medical Education and Patient Access (2015)

• Taking Charge: A Handbook For Health Care & Social Service Providers Working With Trans People (2011)

• Gender incongruence: a comparative study using ICD-10 and DSM-5 diagnostic criteria (Oct 7 2017)

Patient Care

• Simulation Design: Addressing Care of a Transgender Patient (September 2017)Original

• Caring for the Transgender Patient(June 2017)Original

• Transgender Youth: Current Concepts (December 2016)

• Caring For Transgender Adolescents In BC: Suggested Guidelines (2006)

• Best practices in LGBT care: A guide for primary care physicians (July 2016)

Neuroscience

• Brain sexual differentiation and effects of cross-sex hormone therapy in transpeople: A resting-state functional magnetic resonance study (October 2017)Original

• Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals (August 2017)

• Serum concentrations of brain-derived neurotrophic factor in patients diagnosed with gender dysphoria undergoing sex reassignment surgery. (March 2017)Original

• Testosterone Effects on the Brain in Transgender Men (March 2017)Original

• Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration (December 2016)Original

• Circulating androgens correlate with resting-state MRI in transgender men (November 2016)Original

• Gender transition affects neural correlates of empathy: A resting state functional connectivity study with ultra high-field 7T MR imaging (September 2016)Original

• A Structural Magnetic Resonance Imaging Study in Transgender Persons on Cross-Sex Hormone Therapy(August 2016)Original

• Neuroimaging studies in people with gender incongruence (January 2016)Original

• High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender PeopleOriginal

• Regional volumes and spatial volumetric distribution of gray matter in the gender dysphoric brain. (May 2015)Original

• Cross-sex hormone treatment in male-to-female transsexual persons reduces serum brain-derived neurotrophic factor (BDNF) (January 2015)Original

Drugs

Spironolactone

• Biorelevant Media Slows the Solution-Mediated Phase Transformation of Amorphous Spironolactone (January 2018)Original

• Testosterone levels achieved by medically treated transgender women in a united states endocrinology clinic cohort (November 2017)Original

• Metabolomics for informing adverse outcome pathways: Androgen receptor activation and the pharmaceutical spironolactone (March 2017)Original

• Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives (February 2017)Original

• Scalp Hair Regrowth in Hormone-Treated Transgender Woman (October 2016)

• Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders(December 2006)Original

• Spironolactone as a single agent for long-term therapy of hirsute patients(May 2000)Original

Cyproterone

• Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment(October 2017)Original

• Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents (May 2017)Original

• Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses? (March 2017)Original

• Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women. (November 2016)Original

• Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness (August 2016)Original

Leuprolide

• Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh (June 2016)

• Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl (November 2015)Original

• Leuprolide Acetate Inhibits Spinal Cord Inflammatory Response in Experimental Autoimmune Encephalomyelitis by Suppressing NF-κB Activation (October 2015)Original

• Leuprolide acetate-stimulated androgen response during female puberty (January 2015)(July 2015 Original

• Aqueous stability of leuprolide acetate: effect of temperature, dissolved oxygen, pH and complexation with β-cyclodextrin (October 2014)Original

• Leuprolide acetate: pharmaceutical use and delivery potentials (February 2012)Original

• A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients (July 2011)

• Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery (March 2011)Original

• Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study (April 2010)Original

• Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas (July 2008)Original

• Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer (May 2008)Original

• Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study (December 2004)Original

• Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males (December 2004)

• Comparison Between a Single Dose of Goserelin (Depot) and Multiple Daily Doses of Leuprolide Acetate for Pituitary Suppression in IVF Treatment: A Clinical Endocrinological Study of the Ovarian Response(July 2002)

• Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy (February 2002)Original

Bicalutamide

• Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9 (December 2017)Original

• Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen (December 2017)Original

• Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade (July 2016)

• Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations (December 2015)Original

• A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide (August 2015Original

• Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans (January 2015)Original

• Binding of a Cyano- and Fluoro-containing Drug Bicalutamide to Cytochrome P450 46A1 (February 2015)

• Species-dependent binding of new synthesized bicalutamide analogues to albumin by optical biosensor analysis(February 2015)Original

• Optical biosensor analysis in studying new synthesized bicalutamide analogs binding to androgen receptor (July 2014)Original

• The relative bioavailability study and fasting and fed states pharmacokinetics of bicalutamide 50-mg tablets in healthy Chinese volunteers (January 2012)Original

• Formation of bicalutamide nanodispersion for dissolution rate enhancement (February 2011)Original

• Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity (May 2010)Original

• Mechanistic studies on the synthesis of bicalutamide (February 2009)Original

• Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT Corepressors (September 2007

• Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor (May 2002)

Enzalutamide

• Drug-drug interaction potential in men treated with enzalutamide: Mind the gap (January 2018)Original

• Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters (December 2017)Original

• Absorption, Distribution, Metabolism, and Excretion of the Androgen Receptor Inhibitor Enzalutamide in Rats and Dogs (August 2017)Original

Tamoxifen

• Effects of tamoxifen on neuronal morphology, connectivity and biochemistry of hypothalamic ventromedial neurons: Impact on the modulators of sexual behavior (January 2018)Original

• Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives (January 2018)Original

• A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy(August 2017)Original

• Mechanism of Off-Target Interactions and Toxicity of Tamoxifen and Its Metabolites (July 2017)Original

• The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis (June 2017)

• Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity (March 2017)

• Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development (December 2016)

• Tamoxifen Resistance: Emerging Molecular Targets (August 2016)

• Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system (August 2016)

• Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery (August 2016)

• Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity (May 2016)

• Tamoxifen regulation of sphingolipid metabolism—therapeutic implications (May 2015)

• CB1 and CB2 Receptors are Novel Molecular Targets for Tamoxifen and 4OH-Tamoxifen (November 2014)

• Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review (August 2012)

• Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study (July 2007)Original

Afimoxifene

• Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status (September 2015)

• Synthesis and Characterizaton of Fluorescent 4-Hydroxytamoxifen Conjugates with Unique Antiestrogenic Properties (May 2010)

• 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ (July 2001)

Toremifene

• Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes (October 2015)Original

• Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer (August 2015)Original

• Sulfation of 4-Hydroxy Toremifene: Individual Variability, Isoform Specificity, and Contribution to Toremifene Pharmacogenomics (June 2012)

• Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: endogenous steroids urinary profile after multiple oral doses (November 2011)Original

• Toremifene: an evaluation of its safety profile (April 2006)Original

• Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor (August 2009)Original

• Influence of age on toremifene pharmacokinetics (December 1996)Original

Endoxifen

• Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen (October 2016)

• Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold (September 2016)

• Boronic Prodrug of Endoxifen as an Effective Hormone Therapy for Breast Cancer (July 2016)

• Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies (October 2014)

• Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells (May 2014)

• Structure Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen (April 2010)

Fulvestrant-3-boronic acid

• Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)(October 2017)

• Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD) (September 2016)

Raloxifene

• Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study (December 2017)Original

• Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study (May 2016)Original

• Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women (January 2005)Original

• Adrenal function under long-term raloxifene administration (April 2003)Original

Finasteride

• Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men (December 2017)Original

• Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients (October 2017)Original

• Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients (July 2017)Original

• 5-Alpha-Reductase Inhibitors and Combination Therapy (August 2016)Original

• Opposite effects of dihydrotestosterone and estradiol on apoptosis in the anterior pituitary gland from male rats (March 2016)Original

• Comparison of clinical trials with finasteride and dutasteride (September 2004)

Biological Mechanisms

DMRT1/SOX9 + FOXL2/WNT-4/β-catenin

• An ancient protein-DNA interaction underlying metazoan sex determination (April 2015)Original

• Sexual Cell-Fate Reprogramming in the Ovary by DMRT1 (March 2015)

• FOXL2: A Central Transcription Factor in the Ovary (February 2014)

• Antagonistic roles of Dmrt1 and Foxl2 in sex differentiation via estrogen production in tilapia as demonstrated by TALENs (December 2013)

• Sex and the singular DM domain: insights into sexual regulation, evolution and plasticity (February 2012)Original

• DMRT1 prevents female reprogramming in the postnatal mammalian testis (August 2011)

• Failure of SOX9 Regulation in 46XY Disorders of Sex Development with SRY, SOX9 and SF1 Mutations (March 2011)

• Sex determination and the control of Sox9 expression in mammals (February 2011)

• Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific Promoter (December 2010)

• Doublesex- and Mab-3-Related Transcription Factor-1 Repression of Aromatase Transcription, a Possible Mechanism Favoring the Male Pathway in Tilapia (March 2010)

• Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation (December 2009)

• Females battle to suppress their inner male (December 2009)

• The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation (June 2009)

• Activation of b-catenin signaling by Rspo1 controls differentiation of the mammalian ovary (February 2008)

• Gonadal sex reversal in mutant Dax1 XY mice: a failure to upregulate Sox9 in pre-Sertoli cells (July 2005)

• SRY, SOX9, and DAX1 expression patterns during human sex determination and gonadal development (March 2000)

Androgen Receptors

• Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer (September 2014)

• Androgen receptor epigenetics review article (September 2013)

• Identification of novel androgen receptor antagonists using structure- and ligand-based methods (January 2013)Original

• Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist (June 2012)

• Nonsteroidal Androgen Receptor Ligands: Versatile Syntheses and Biological Data (June 2012)

• Developments in nonsteroidal antiandrogens targeting the androgen receptor (October 2010)Original

• New Selective Estrogen and Androgen Receptor Modulators (July 2010)

• Alternative inhibition of androgen receptor signaling: Peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors (June 2010)

• The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells (June 2007)

• Circumventing Anti-Androgen Resistance by Molecular Design (April 2007)

• A novel class of pyranocoumarin anti-androgen receptor signaling compounds (March 2007)Original

• Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones (March 2007)Original

• The Corepressors Silencing Mediator of Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Are Involved in Agonist- and Antagonist-Regulated Transcription by Androgen Receptor (May 2006)

• LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription (July 2005)Original

• The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists (December 2004)

• Androgen Regulation of the Human Hair Follicle: The Type I Hair Keratin hHa7 Is a Direct Target Gene in Trichocytes (March 2004)

• Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor (January 2004)

• Formation of the Androgen Receptor Transcription Complex (March 2002)

Estrogen Receptors

• Chlorinated biphenyls effect on estrogen-related receptor expression, steroid secretion, mitochondria ultrastructure but not on mitochondrial membrane potential in Leydig cells (March 2017)

• Molecular mechanism of estrogen–estrogen receptor signaling (January 2017)

• Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity (December 2016)

• A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β (August 2016)

• Predictive features of ligand‐specific signaling through the estrogen receptor (April 2016)

• The Molecular, Cellular and Clinical Consequences of Targeting the Estrogen Receptor Following Estrogen Deprivation Therapy (June 2015)

• Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element (May 2015)

• Selective estrogen receptor modulators: tissue specificity and clinical utility (August 2014)

• Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway (July 2014)

• In Vitro and in Vivo Molecular Imaging of Estrogen Receptor α and β Homo- and Heterodimerization: Exploration of New Modes of Receptor Regulation (November 2011)

• High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes (May 2011)

• A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer (May 2011)

• Unique Ligand Binding Patterns Between Estrogen Receptor α and β Revealed by Hydrogen/Deuterium Exchange (October 2009)

• Selective Estrogen Receptor Modulators 4-Hydroxytamoxifen and Raloxifene Impact the Stability and Function of SRC-1 and SRC-3 Coactivator Proteins (January 2004)

• Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β (March 1999)

Aromatase

• Ergostane-Type Sterols from King Trumpet Mushroom (Pleurotus eryngii) and Their Inhibitory Effects on Aromatase (November 2017)

• Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies (October 2017)

• High-Throughput Analysis of Ovarian Cycle Disruption by Mixtures of Aromatase Inhibitors (July 2017)

• Aromatase inhibitory activity of 1,4-naphthoquinone derivatives and QSAR study (May 2017)

• Six new ergostane-type steroids from king trumpet mushroom (Pleurotus eryngii) and their inhibitory effects on nitric oxide production (November 2016)

• Relationship Between Breast Density and Selective Estrogen-Receptor Modulators, Aromatase Inhibitors, Physical Activity, and Diet (April 2016)

• Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure–Function Perspective (January 2016)

• Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors that Also Modulate Estrogen Receptors (December 2015)

• Modulation of Aromatase by Phytoestrogens (December 2015)

• Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis (September 2015)

• Local Transformations of Androgens into Estradiol by Aromatase P450 Is Involved in the Regulation of Prolactin and the Proliferation of Pituitary Prolactin-Positive Cells (June 2014)

• Dynamics and Flexibility of Human Aromatase Probed by FTIR and Time Resolved Fluorescence Spectroscopy (December 2013)

• Molecular Simulations of Aromatase Reveal New Insights Into the Mechanism of Ligand Binding (August 2013)

• Testosterone-derived estradiol production by male endothelium is robust and dependent on p450 aromatase via estrogen receptor alpha (May 2013)

• Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)aminomethyl}phenyl sulfamate (March 2013)

• Development of a new class of aromatase inhibitors: Design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives (February 2012)

• Sex Differences in Brain Aromatase Activity: Genomic and Non-Genomic Controls (August 2011)

• Aromatase, Estrone Sulfatase, and 17β-Hydroxysteroid Dehydrogenase: Structure-Function Studies and Inhibitor Development (October 2010)

• Diversity of mechanisms involved in aromatase regulation and estrogen action in the brain (January 2010)

• Sequence-function correlation of aromatase and its interaction with reductase (November 2009)

• Regulation of aromatase induction by nuclear receptor coregulator PELP1 (September 2009)

• The Critical Iron-Oxygen Intermediate in Human Aromatase (September 2009)

• Antiestrogen pathway (aromatase inhibitor) (July 2010)

• Structural basis for androgen specificity and oestrogen synthesis in human aromatase (February 2010)

• Xanthones from the Botanical Dietary Supplement Mangosteen (Garcinia mangostana) with Aromatase Inhibitory Activity (June 2008)

• Aromatase Expression in the Ovary: Hormonal and Molecular Regulation (February 2008)

Methods

• Self-Assembly of Stable Monomolecular Nucleic Acid Lipid Particles with a Size of 30 nm